Oculis Holding AG
OCS | IC
Overview
Corporate Details
- ISIN(s):
- CH1242303498 (+1 more)
- LEI:
- 5067005370C2KK324336
- Country:
- Switzerland
- Address:
- Bahnhofstrasse 7, 6300 Zug
- Website:
- https://www.oculis.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative treatments to save sight and improve eye care. The company's primary mission is to address significant unmet medical needs in ophthalmology through a patient-centric approach. Its pipeline features several investigational drug candidates, including OCS-01, a topical eye drop using its proprietary OPTIREACH® technology for Diabetic Macular Edema (DME); Licaminlimab (OCS-02) for Dry Eye Disease (DED); and Privosegtor (OCS-05), a neuroprotective agent for Acute Optic Neuritis. Oculis aims to develop highly differentiated, non-invasive, and potentially first-in-class therapies to transform the treatment paradigms for major eye diseases.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Oculis Holding AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-25 10:00 |
Board/Management Information
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-R…
|
English | 13.2 KB | |
| 2025-08-21 22:05 |
Earnings Release
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
|
Icelandic | 20.6 KB | |
| 2025-08-21 22:05 |
Earnings Release
Oculis Reports Q2 2025 Financial Results and Provides Company Update
|
English | 18.3 KB | |
| 2025-08-12 10:00 |
Report Publication Announcement
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtu…
|
English | 4.2 KB | |
| 2025-08-01 10:00 |
Capital/Financing Update
Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF
|
Icelandic | 8.1 KB | |
| 2025-08-01 10:00 |
Capital/Financing Update
Oculis Upsized Loan Facility to Access up to CHF 100 million
|
English | 7.1 KB | |
| 2025-07-09 22:05 |
Board/Management Information
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 948 bytes | |
| 2025-06-09 22:05 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 940 bytes | |
| 2025-06-05 10:00 |
Post-Annual General Meeting Information
Oculis birtir niðurstöður aðalfundar 2025
|
Icelandic | 7.7 KB | |
| 2025-06-05 10:00 |
Post-Annual General Meeting Information
Oculis Publishes Results of 2025 Annual General Meeting
|
English | 6.4 KB | |
| 2025-06-03 23:00 |
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
|
English | 949 bytes | |
| 2025-06-03 10:00 |
Regulatory News Service
Oculis to Participate in Upcoming June Investor Conferences
|
English | 4.3 KB | |
| 2025-05-09 22:05 |
Pre-Annual General Meeting Information
Oculis birtir boð á aðalfund
|
Icelandic | 4.6 KB | |
| 2025-05-09 22:05 |
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the Annual General Meeting
|
English | 4.2 KB | |
| 2025-05-09 21:05 |
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the ..
|
Icelandic | 4.6 KB |
Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oculis Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
